Basecamp Research
London company using AI and biological data for drug discovery.
Basecamp Research designs potential medicines using biological data and its EDEN models. Its London-based business combines computational design with technology for introducing DNA sequences into cells.
Last refreshed: 22 October 2026 · Appears in 1 active topic
Timeline for Basecamp Research
Closed a £105.6m Series C
UK Startups and Innovation: Basecamp Research, TrueLayer and three regional firms raiseBackground
Basecamp Research is a biotechnology company headquartered in London, with offices and laboratories in Cambridge, Massachusetts. It trains computational models for therapeutic design using proprietary biological data. Its EDEN models draw on the Trillion Gene Atlas, a dataset assembled through international access and benefit-sharing partnerships. [Basecamp Research](https://www.basecamp-research.com/news-research/basecamp-research-raises-140m-to-advance-ai-designed-therapeutics)
The company combines those models with technology for writing DNA sequences into cells. One application is in vivo cell therapy, which aims to alter cells within a patient's body. Its design work also covers enzymes and peptides. It works with pharmaceutical partners to take candidates into development. Designing a candidate is an early step towards a medicine; the company's described pipeline is advancing from preclinical work towards clinical development. [Technology and development](https://www.basecamp-research.com/news-research/basecamp-research-raises-140m-to-advance-ai-designed-therapeutics)
What did Basecamp Research raise in September 2026?
What will Basecamp Research use the funding for?
What stage are Basecamp Research's medicines at?
Written with AI from Lowdown's published reporting. Not individually reviewed by an editor. Updated 22 October 2026. Editorial standards.